Teriparatide

At a glance

---

What is teriparatide?

Teriparatide is a recombinant peptide consisting of the first 34 amino acids of human parathyroid hormone — the N-terminal fragment of full-length PTH(1-84). This 1-34 fragment retains all of the receptor-binding and biological activity of native PTH while being short enough to manufacture reliably by recombinant DNA technology in E. coli.^[8]

It was developed by Eli Lilly and approved by the FDA in November 2002 under the brand name Forteo for postmenopausal women with osteoporosis at high fracture risk; men with primary or hypogonadal osteoporosis at high fracture risk; and men and women with glucocorticoid-induced osteoporosis at high fracture risk.^[1] A biosimilar, Bonsity, was approved in the United States in 2019, and a generic teriparatide injection was approved in 2024. In Europe it has been available as Forsteo since 2003, with biosimilars Movymia and Terrosa approved in 2017.

Why this matters in the peptide landscape. Teriparatide is a real, FDA-approved peptide medicine that almost nobody discusses as "a peptide" — it sits firmly in the world of endocrinology and rheumatology rather than in the peptide-curious consumer space. It is one of the few peptide drugs to clear the full FDA approval bar, with biosimilars and a generic, and it represents one of the most important advances in osteoporosis treatment in the last twenty-five years.

---

How it works

Teriparatide binds the PTH1 receptor on osteoblasts (bone-forming cells) and on the osteoblast lineage including osteocytes. The receptor is the same one engaged by endogenous PTH; the unusual part is the dosing pattern.

The defining mechanistic insight of teriparatide is pulsatility. Continuous PTH excess — as in primary hyperparathyroidism — drives net bone resorption: the osteoclasts win. But intermittent (once-daily) PTH(1-34) dosing produces a brief PTH pulse that is cleared within hours, and this pulsatile pattern preferentially activates osteoblasts more than osteoclasts. The net result is bone formation > resorption, producing increased trabecular and cortical bone, increased trabecular thickness and connectivity, and higher BMD.^[1]

This anabolic effect is genuinely different from the antiresorptive mechanism of bisphosphonates and denosumab. Antiresorptives slow the loss of existing bone; teriparatide adds new bone.

Detailed mechanism (for advanced readers)

Teriparatide's mechanism of action is identical to native PTH(1-84) at the receptor level, but the pharmacokinetic profile of daily subcutaneous injection produces a fundamentally different biological outcome:

• Primary target: PTH1 receptor (PTHR1), a class B G-protein-coupled receptor expressed on osteoblasts, osteocytes, and renal tubular cells.
• Signaling cascade: Gs-coupled activation of adenylyl cyclase increases intracellular cAMP and activates PKA; secondary signaling via Gq/PLC/IP3 also occurs. PKA-driven CREB phosphorylation up-regulates osteoblast survival and gene transcription.
• Pulsatile vs. tonic exposure: A daily 20 mcg subcutaneous dose produces a peak serum concentration around 30 minutes post-injection and is cleared within ~3 hours. This brief pulse activates osteoblast survival pathways and transiently down-regulates sclerostin, while not sustaining the osteoclast-stimulating effects seen with continuous PTH excess.
• Histomorphometric effects: Increased mineralizing surface, increased bone formation rate at the tissue level, increased trabecular bone volume, increased trabecular thickness and connectivity, and increased cortical thickness.
• Sclerostin and Wnt: Pulsatile PTH transiently suppresses sclerostin (a Wnt antagonist), de-repressing osteoblast Wnt signaling — a complementary mechanism to direct osteoblast activation.^[8]

How it compares to related compounds:

• vs. Abaloparatide (Tymlos): A synthetic analog of PTHrP (parathyroid-hormone-related peptide), 34 amino acids, PTH1R-selective. The ACTIVE trial (Miller 2016) compared abaloparatide vs placebo with a teriparatide arm; both anabolic agents reduced vertebral fractures, with some differences in nonvertebral fracture and BMD profiles.
• vs. Bisphosphonates (alendronate, risedronate, zoledronic acid): Antiresorptive — they inhibit osteoclasts and slow bone loss. The VERO trial demonstrated teriparatide is superior to risedronate for severe osteoporosis.
• vs. Denosumab (Prolia): A monoclonal antibody against RANKL — also antiresorptive. Often used as follow-on therapy after a course of teriparatide to consolidate gains.
• vs. Romosozumab (Evenity): A monoclonal antibody against sclerostin with both anabolic and antiresorptive components. The other modern anabolic option.

---

What the research says

Teriparatide has one of the strongest evidence bases in osteoporosis medicine. The pivotal Fracture Prevention Trial established a 65% reduction in vertebral fractures; the VERO head-to-head trial established superiority over a bisphosphonate. The original boxed warning, derived from rat data, was removed in 2020 after 15 years of post-marketing surveillance found no human signal.

Research timeline

Teriparatide's development traces a clean arc — from the recognition that pulsatile PTH is anabolic, through pivotal trials, FDA approval, and finally the long-running surveillance that allowed the boxed warning to be lifted:

The Fracture Prevention Trial

The 2001 Neer et al. NEJM paper — the Fracture Prevention Trial (FPT) — is the foundational human evidence for teriparatide and one of the most important osteoporosis trials of the last quarter century.^[1]

In 1,637 postmenopausal women with at least one prior vertebral fracture, daily subcutaneous teriparatide (20 mcg or 40 mcg) was compared with placebo over a median of 21 months. Key findings at the 20 mcg dose (the dose that became the FDA-approved dose):

• New vertebral fractures reduced by 65% (RR 0.35, 95% CI 0.22-0.55)
• Nonvertebral fragility fractures reduced by 53% (RR 0.47, 95% CI 0.25-0.88)
• Lumbar spine BMD increased by 9-13% at 21 months
• Femoral neck BMD increased by ~3%

The trial was stopped early — not because of a problem in the trial itself, but because parallel Long-Evans rat carcinogenicity studies revealed dose- and duration-dependent osteosarcoma. The decision to stop early was made out of an abundance of caution; no osteosarcoma was observed in the human trial, and none has been observed in the more than 15 years of post-marketing surveillance that followed.

VERO: head-to-head vs bisphosphonates

For nearly two decades after the FPT, the central clinical question was: how does teriparatide compare to the standard antiresorptive treatments? Most patients with osteoporosis are first offered a bisphosphonate; teriparatide was reserved for those at very high fracture risk or who failed first-line therapy. The VERO trial finally answered the question with a fracture-endpoint head-to-head comparison.^[2]

VERO randomized 1,360 postmenopausal women with severe osteoporosis (defined as ≥2 prior vertebral fractures, or 1 prior vertebral fracture plus a high T-score deficit) to teriparatide 20 mcg daily or risedronate 35 mg weekly for 24 months. The double-blind, double-dummy design meant patients in each arm received both an active drug and a matching placebo for the other treatment.

Key findings:

• New vertebral fractures: 5.4% (teriparatide) vs 12.0% (risedronate) — a 56% relative risk reduction
• Clinical fractures (a category that includes nonvertebral): 4.8% vs 9.8% — a 52% relative risk reduction
• Pooled clinical and morphometric vertebral fractures: also significantly reduced

VERO was the first head-to-head fracture-endpoint trial of an anabolic agent vs an antiresorptive. It established that for severe osteoporosis specifically — patients at very high fracture risk — anabolic-first treatment is more effective than the standard bisphosphonate first-line approach.

Glucocorticoid-induced osteoporosis

Long-term glucocorticoid therapy (for autoimmune disease, transplant maintenance, COPD exacerbations, and many other indications) is a leading cause of secondary osteoporosis. Glucocorticoids drive bone loss by suppressing osteoblast function and increasing osteoclast survival — a mechanism for which an anabolic agent is conceptually well-matched.^[3]

The Saag 2007 NEJM trial (n=428) randomized men and women on chronic glucocorticoids (≥5 mg prednisone daily) to teriparatide or alendronate for 18 months. Results:

• Lumbar spine BMD: +7.2% (teriparatide) vs +3.4% (alendronate) at 18 months (P<0.001)
• New vertebral fractures: 0.6% (teriparatide) vs 6.1% (alendronate) (P=0.004)
• No significant difference in nonvertebral fractures in this moderate-sized trial

The Saag 2007 trial established teriparatide as a preferred agent for glucocorticoid-induced osteoporosis, particularly for patients at high fracture risk. The American College of Rheumatology guidelines reflect this preference.

The combined evidence base is unusual for an osteoporosis drug: a pivotal placebo-controlled fracture trial (Neer 2001), a head-to-head fracture trial vs a bisphosphonate (Kendler 2018), pivotal data in a major secondary indication (Saag 2007), and a 15-year post-marketing safety surveillance program. There are very few peptide medicines with this depth of human data.

---

What the evidence shows

People encounter teriparatide through different lenses — postmenopausal osteoporosis, glucocorticoid-induced bone loss, severe disease after a bisphosphonate failure, or the safety story around the boxed warning. Here's what the published research actually supports:

---

Safety & side effects

What the Phase 3 data and prescribing information show

Teriparatide has the most comprehensive safety dataset of any peptide-based osteoporosis treatment, documented in its FDA-approved prescribing information from the pivotal trials and a 15-year post-marketing surveillance program:^[8]

Common adverse events (from prescribing information):

• Nausea (~8-9%)
• Dizziness (~8%)
• Leg cramps (~3%)
• Arthralgia (joint pain)
• Headache
• Asthenia (weakness)
• Mild, transient hypercalcemia (peaks 4-6 hours post-injection)
• Hypercalciuria (increased urinary calcium)
• Orthostatic hypotension shortly after early doses (typically self-limited)

Less common but clinically important:

• Persistent hypercalcemia (uncommon at the 20 mcg dose)
• Increase in serum uric acid (rarely clinically significant)
• Injection-site reactions (typically mild)

Hypercalcemia and dosing

Because PTH(1-34) increases calcium mobilization from bone and renal calcium reabsorption, transient hypercalcemia is a predictable pharmacological effect. The clinical practice is to measure serum calcium 4-6 hours after a dose only if there is concern; in routine use, persistent hypercalcemia is uncommon at the approved 20 mcg daily dose. Patients with pre-existing hypercalcemia, primary hyperparathyroidism, or active urolithiasis are not candidates for teriparatide.

The boxed warning history

This is one of the most interesting regulatory stories in peptide medicine and warrants its own section.

The boxed warning history (and 2020 revision)

When teriparatide was approved in November 2002, its label carried a boxed warning about the risk of osteosarcoma — the strongest type of warning the FDA can apply short of withdrawing a drug. The label also imposed a 2-year cumulative lifetime treatment limit.^[10]

The basis for both restrictions was a single set of preclinical findings. In Long-Evans rat carcinogenicity studies conducted alongside the pivotal trial program, young rats given daily subcutaneous teriparatide for nearly their entire lifespan developed dose- and duration-dependent osteosarcoma — a cancer of the bone-forming cells. The finding was real, robust, and obviously concerning: a drug whose mechanism is to stimulate osteoblasts had caused tumors of those same cells in rats.

But several features of the rat study were unusual when translated to human use. The rats received the equivalent of 3-60 times the human dose, on a mg/kg basis. They received it for nearly their entire lifespan, starting at 2 months of age. Long-Evans rats have continuously growing skeletons and unusually high baseline rates of spontaneous bone abnormalities. None of these conditions resemble adult human use of teriparatide for osteoporosis.

To find out whether the rat signal would translate, the manufacturer and the FDA established the Osteosarcoma Surveillance Study — a population-based observational program that linked US cancer registries with teriparatide-exposure histories. The program ran for 15 years.

The interim 7-year results (Andrews 2012) found no association between teriparatide and adult osteosarcoma.^[5] The final 15-year results (Gilsenan 2021) confirmed: across the entire surveillance period, in the population of US adults treated with teriparatide, there was no increased risk of osteosarcoma.^[6]

In November 2020, the FDA acted on this evidence: it removed the boxed warning about osteosarcoma and removed the 2-year cumulative lifetime treatment limit from the Forteo label.^[9] Teriparatide can now be used beyond 24 months when clinically appropriate, with standard prescribing-information safety monitoring rather than a boxed-warning level of caution.

Contraindications and interactions

Contraindications (from prescribing information):

• Pre-existing hypercalcemia
• Severe renal impairment
• Pregnancy and lactation
• Known hypersensitivity to teriparatide or its excipients
• Conditions associated with increased baseline risk of osteosarcoma — Paget's disease of bone, unexplained elevations of alkaline phosphatase, prior external beam or implant radiation therapy involving the skeleton, or open epiphyses (pediatric and young adult patients). Teriparatide is not indicated in pediatric patients.
• Bone metastases or a history of skeletal malignancy

Key precautions:

• Orthostatic hypotension may occur within 4 hours of dosing — patients should be in a position to sit or lie down if symptoms develop
• Use with caution in patients with active or recent urolithiasis
• Monitor serum calcium periodically in patients on concomitant cardiac glycosides (digoxin) — hypercalcemia can predispose to digoxin toxicity
• Sequential anti-resorptive therapy is generally recommended after the anabolic course to consolidate BMD gains

---

How people use it

Teriparatide is a prescription FDA-approved medicine, and its use is governed by standard prescribing-information guidance and clinical judgment.

FDA-approved use

For all approved indications (postmenopausal osteoporosis at high fracture risk; men with primary or hypogonadal osteoporosis at high fracture risk; glucocorticoid-induced osteoporosis at high fracture risk), teriparatide is prescribed at 20 mcg subcutaneously once daily, injected into the thigh or abdominal wall using a multi-dose pre-filled pen.

The standard treatment course is now flexible — historically restricted to 24 months by the lifetime limit, the 2020 label revision allows treatment beyond 24 months when clinically appropriate. In practice, most patients still receive a course of 18-24 months and are then transitioned to an antiresorptive agent.

Sequential therapy

A defining feature of teriparatide use is the sequential-therapy framework. Because BMD gains decline if no follow-on therapy is given, current osteoporosis guidelines recommend transitioning patients from teriparatide to an antiresorptive agent (most commonly a bisphosphonate or denosumab) after the anabolic course. The EUROFORS substudy and related extension data provide the evidence base for this practice.^[4]

Off-label context

Off-label use of teriparatide is uncommon. Niche off-label applications include adjunctive use to accelerate fracture healing in select non-union or atypical femoral fracture cases, and limited use in osteonecrosis of the jaw — but these are specialist applications, not consumer-facing peptide use. Teriparatide is not used in the anti-aging or "wellness" peptide space in any meaningful way; it is too expensive, too narrowly indicated, and too closely tied to a specific clinical condition.

---

Legal & regulatory status

As of April 2026:

FDA status

Teriparatide is currently FDA-approved as Forteo (Eli Lilly), Bonsity (biosimilar, 2019), and as a generic teriparatide injection (2024) for: postmenopausal women with osteoporosis at high fracture risk; men with primary or hypogonadal osteoporosis at high fracture risk; and men and women with glucocorticoid-induced osteoporosis at high fracture risk.^[8]

The approval and labeling history:

1. November 2002: Original Forteo approval with boxed warning and 2-year lifetime limit
2. 2007: Glucocorticoid-induced osteoporosis indication added based on Saag 2007 trial
3. 2019: First US biosimilar (Bonsity) approved
4. November 2020: Boxed warning about osteosarcoma and the 2-year cumulative lifetime treatment limit removed
5. 2024: Generic teriparatide injection approved

WADA / USADA status

Teriparatide is not specifically prohibited by the World Anti-Doping Code. It is not a performance-enhancing substance and does not appear on the WADA Prohibited List. Use is governed by standard medical-treatment principles.

International status

Teriparatide is approved in the European Union as Forsteo (originally 2003), with biosimilars Movymia and Terrosa (both 2017) and Livogiva (2020). It is also approved in the UK, Canada, Japan, Australia, and most other major markets for similar osteoporosis indications.

---

How teriparatide compares

Teriparatide sits in a small landscape of anabolic osteoporosis agents. Here's how it compares to its closest peer (the other PTH-pathway anabolic, abaloparatide) and to a representative bisphosphonate (alendronate, the most commonly prescribed antiresorptive):

The comparison illustrates where teriparatide fits in the osteoporosis treatment landscape. Both teriparatide and abaloparatide are PTH-pathway anabolic agents — different molecules but the same conceptual approach. Abaloparatide (Tymlos), approved in 2017, is a synthetic analog of PTHrP (parathyroid-hormone-related peptide) that is selective for one of the conformations of the PTH1 receptor. The pivotal ACTIVE trial (Miller 2016) showed abaloparatide reduces vertebral fractures vs placebo, with some differences from teriparatide in BMD trajectory and side-effect profile.^[11]

Alendronate (Fosamax) — the most commonly prescribed osteoporosis drug worldwide — represents the antiresorptive alternative. Bisphosphonates have an enormous evidence base, are inexpensive (now generic), and have a well-characterized safety profile. For most patients with osteoporosis at moderate fracture risk, a bisphosphonate is appropriate first-line. For severe osteoporosis at very high fracture risk, the VERO trial supports anabolic-first treatment with teriparatide.

The most common practice pattern is now: anabolic agent first (teriparatide or abaloparatide) for severe disease, followed by an antiresorptive (bisphosphonate or denosumab) to consolidate gains.

---

Common exaggerations to watch for

Teriparatide has a strong evidence base, but it is sometimes described in ways that go beyond the actual evidence. Here are the most common exaggerations or misunderstandings:

• "Teriparatide causes bone cancer" — Incorrect, on current evidence. The original boxed warning was driven by Long-Evans rat data. The 15-year human surveillance program found no signal in adults treated with teriparatide. The FDA removed the boxed warning in November 2020. The rat finding is now understood as a species- and protocol-specific artifact.
• "Teriparatide can be used indefinitely" — Overstated. The 2-year lifetime limit was removed in November 2020, and treatment beyond 24 months is now permitted when clinically appropriate. But the long-term efficacy and safety data beyond two years is more limited than within the initial treatment window.
• "BMD gains are permanent" — Incorrect. BMD gains decline after teriparatide is stopped unless followed by an antiresorptive. Sequential therapy is the standard of care.
• "Teriparatide cures osteoporosis" — No. Teriparatide builds bone and reduces fracture risk, but osteoporosis is a chronic condition. After the anabolic course, ongoing antiresorptive therapy is generally required to maintain the gains.
• "Anabolic therapy is always better than bisphosphonates" — Overstated. For severe osteoporosis at very high fracture risk, the VERO data support anabolic-first treatment. For moderate-risk patients, bisphosphonates remain appropriate first-line and are far less expensive.
• "Teriparatide is just the same as taking PTH" — Misleading. Continuous PTH excess (as in primary hyperparathyroidism) causes net bone resorption. The anabolic effect of teriparatide depends entirely on pulsatile dosing — the brief daily PTH spike followed by clearance. The pattern is the medicine.

---

Related content

Peptide

Tesamorelin Profile

Another FDA-approved peptide drug. A useful comparison for understanding the regulatory and evidence standards that approved peptide medicines meet.

Peptide

Elamipretide Profile

FDA-approved peptide drug for Barth syndrome. Another example of a peptide that crossed the full FDA approval bar — useful context for the small set of peptide medicines.

Guide

What Are Peptides?

A grounded explainer on what peptides actually are. Teriparatide is a textbook example of a recombinant peptide hormone medicine.

News

FDA Peptide Categories Explained

How the FDA categorizes peptide drugs, biologics, and compounded peptides. Teriparatide sits in the most-regulated category — full NDA approval with biosimilars and a generic.

---

References

1. [1]

   Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al.. “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.” N Engl J Med. 2001. 344(19):1434-1441 DOI PubMedRCT

   Pivotal Fracture Prevention Trial. n=1,637, median 21 months. Published in NEJM. Demonstrated 65% reduction in new vertebral fractures and 53% reduction in nonvertebral fragility fractures. Trial stopped early due to rat osteosarcoma signal.

2. [2]

   Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al.. “Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.” Lancet. 2018. 391(10117):230-240 DOI PubMedRCT

   VERO trial. n=1,360, 24 months. First head-to-head fracture-endpoint trial of teriparatide vs an antiresorptive (risedronate). Demonstrated superiority of anabolic over antiresorptive in severe osteoporosis.

3. [3]

   Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al.. “Teriparatide or alendronate in glucocorticoid-induced osteoporosis.” N Engl J Med. 2007. 357(20):2028-2039 DOI PubMedRCT

   Pivotal trial in glucocorticoid-induced osteoporosis. n=428, 18 months. Teriparatide superior to alendronate for BMD and vertebral fracture endpoints.

4. [4]

   Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, et al.. “Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.” J Bone Miner Res. 2008. 23(10):1591-1600 DOI PubMedRCT

   EUROFORS substudy. Examined the influence of prior antiresorptive therapy on response to teriparatide. Provides extension and sequential-therapy data informing post-anabolic management.

5. [5]

   Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al.. “The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.” J Bone Miner Res. 2012. 27(12):2429-2437 DOI PubMedSafety study

   Interim results of the Osteosarcoma Surveillance Study. First major post-marketing analysis showing no human osteosarcoma signal after 7 years. Critical evidence in the eventual boxed-warning removal.

6. [6]

   Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. “Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study.” J Bone Miner Res. 2021. 36(2):244-251 DOI PubMedSafety study

   Final 15-year results of the Osteosarcoma Surveillance Study. Supported the FDA's November 2020 decision to remove the boxed warning and the 2-year lifetime limit.

7. [7]

   Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ. “Teriparatide for osteoporosis: importance of the full course.” Osteoporos Int. 2016. 27(8):2395-2410 DOI PubMedReview

   Comprehensive review of teriparatide fracture-risk reduction across baseline severity strata, dosing duration, and persistence after discontinuation.

8. [8]

   Eli Lilly and Company (prescribing information). “FORTEO (teriparatide injection) — Full Prescribing Information.” 2021. Link

   Current FDA-approved prescribing label after the November 2020 revision that removed the boxed warning and 2-year lifetime treatment limit. Definitive source for indications, dosing, contraindications, and adverse-event rates.

9. [9]

   U.S. Food and Drug Administration. “FDA approves removal of boxed warning about risk of bone cancer in patients receiving Forteo (teriparatide).” 2020. Link

   FDA labeling action documenting the removal of the boxed warning concerning osteosarcoma and the 2-year cumulative lifetime treatment limit in November 2020.

10. [10]

    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al.. “Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.” Toxicol Pathol. 2002. 30(3):312-321 DOI PubMedAnimal study

    Original Long-Evans rat carcinogenicity study identifying dose- and duration-dependent osteosarcoma. Drove the original boxed warning. Important for understanding why the rat finding did not translate to humans.

11. [11]

    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al.. “Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (ACTIVE).” JAMA. 2016. 316(7):722-733 DOI PubMedRCT

    Pivotal trial of abaloparatide (Tymlos), the second anabolic PTH-pathway agent. Included a teriparatide comparator arm and is the basis for the abaloparatide vs teriparatide comparison.

---